額顳葉失智症市場－全球產業規模、佔有率、趨勢、機會和預測，按藥物類別、疾病適應症、配銷通路、地區和競爭細分，2020 年至 2030 年

2024 年全球額顳葉失智症市場價值為 2.4136 億美元，預計在預測期內將呈現強勁成長，到 2030 年的複合年成長率為 6.39%。額顳葉疾病是一種神經系統疾病，其特徵是大腦額葉或顳葉神經細胞的退化。這種疾病包括失智症、進行性核上性麻痺和原發性進行性失語症，會嚴重影響行為、語言、運動和個性，進而損害個人的日常活動能力。額顳葉疾病，也稱為額顳葉退化，是一種主要影響額葉和顳葉的腦部疾病。這種疾病的特徵是神經細胞逐漸喪失和失智症的發展。

例如，芬蘭的一項2025年研究比較了245名額顳葉失智症 (FTD) 患者、1300多名阿茲海默症 (AD) 患者以及2400多名年齡、性別和地點匹配的健康對照者的癲癇盛行率和抗癲癇藥物使用情況。 FTD 患者的平均診斷年齡為65歲（女性佔49%），而AD患者的平均診斷年齡為72歲（女性佔59%）。額顳葉失智症的典型發病年齡範圍為40至60歲，但也可能在60歲以後發病。確診後，患者的平均壽命約為8-10年。鑑於其對醫療保健行業的重大影響，預計額顳葉失智症在預測期內將大幅成長。

關鍵市場促進因素

加大FTD藥物研發投入與資金投入

主要市場挑戰

神經系統疾病的誤診

主要市場趨勢

更高的藥品核准和先進的治療

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：臨床試驗分析

第6章：全球額顳葉失智症市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依藥物類別（認知增強劑、抗精神病藥、抗憂鬱劑、中樞神經興奮劑和其他藥物類別）
  • 依疾病指徵（額顳葉失智症、原發性進行性失語症及運動障礙）
  • 按配銷通路（醫院藥房、零售藥房和網路藥房）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第7章：北美額顳葉失智症市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第8章：歐洲額顳葉失智症市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 德國
  • 英國
  • 義大利
  • 法國
  • 西班牙

第9章：亞太地區額顳葉失智症市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第10章：南美額顳葉失智症市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第 11 章：中東和非洲額顳葉失智症市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 12 章：市場動態

• 驅動程式
• 挑戰

第13章：市場趨勢與發展

• 近期發展
• 併購
• 產品發布

第 14 章：全球額顳葉失智症市場：SWOT 分析

第 15 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 16 章：競爭格局

• Transposon Therapeutics
• Alector Inc.
• Denali Therapeutics Inc.
• Pfizer Inc.
• Johnson & Johnson Services Inc.
• Prevail Therapeutics
• Wave Life Sciences
• AstraZeneca plc
• GlaxoSmithKline plc
• TauRx Pharmaceuticals Ltd.

第 17 章：策略建議

第18章調查會社について,免責事項

Global Frontotemporal Dementia Market was valued at USD 241.36 Million in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 6.39% through 2030F. Frontotemporal diseases are a neurological condition characterized by the degeneration of nerve cells in the frontal or temporal lobes of the brain. This condition, which includes dementia, progressive supranuclear palsy, and primary progressive aphasia, significantly impacts behavior, language, movement, and personality, thereby impairing individuals' ability to perform daily activities. Frontotemporal disorders, also known as frontotemporal lobar degeneration, are a type of brain disorder that primarily affects the frontal and temporal lobes. This condition is characterized by the progressive loss of nerve cells and the development of dementia.

For instance, a 2025 study from Finland compared epilepsy prevalence and antiseizure medication use among 245 frontotemporal dementia (FTD) patients, over 1,300 Alzheimer's disease (AD) patients, and more than 2,400 age-, sex-, and location-matched healthy controls. FTD patients had a mean diagnosis age of 65 (49% women), while AD patients averaged 72 years (59% women). The typical age range for the onset of frontotemporal disorder is between 40 and 60 years, although it can occur after the age of 60. Following diagnosis, the average life expectancy is approximately 8-10 years. Given its significant impact on the healthcare sector, it is projected that frontotemporal disorders will experience substantial growth in the forecast period.

Key Market Drivers

Increasing FTD Drug Development and Increasing Funds

Non-profit organizations and disease advocacy groups, as well as private organizations, are currently focused on supporting the development of drugs for Frontotemporal Degeneration (FTD) due to the expanding patient population. Research funding initiatives from notable non-profit organizations, such as the Association for Frontotemporal Degeneration (AFTD), Bluefield Project Organization, Tau Consortium Organization, Alzheimer Discovery Foundation (ADDF), and CurePSP, Inc., have played a significant role in stimulating research efforts for the treatment of frontotemporal disorders. These organizations provide support for both clinical and preclinical trials aimed at testing novel therapeutics that can intervene to slow down or halt the progression of FTD and other rare neurological diseases. This, in turn, contributes to the growth of the market. For instance, a 2025 study revealed that epileptic seizures are significantly more common in patients with frontotemporal dementia (FTD) than previously believed. This finding enhances understanding of FTD symptoms and highlights the need to consider seizures in patient care. Led by Neurocenter Finland, the University of Eastern Finland and University of Oulu conducted the research, published in JAMA Neurology, using one of the world's largest FTD datasets.

Grants and funding provide resources to support FTD-focused research initiatives. This includes investigations into the underlying mechanisms of the disease, identification of potential drug targets, and the development of novel therapeutic approaches. Drug development in FTD necessitates rigorous clinical trials to evaluate the safety and efficacy of potential treatments. Grants and funding support the design, implementation, and monitoring of these trials, facilitating the testing of new therapies. Adequate funding enhances the attractiveness of FTD research for scientists and researchers. This can lead to increased participation, collaboration, and expertise focused on FTD drug development efforts. Funding enables the exploration of innovative therapeutic strategies, including small molecules, biologics, gene therapies, and personalized medicine approaches tailored to the unique characteristics of FTD patients. Grants and funding assist in the identification and validation of promising drug targets for FTD. This step is crucial in developing treatments that address the underlying causes of the disease.

Key Market Challenges

Misdiagnosis of Neurological Disorders

Multiple frontotemporal disorders are frequently misdiagnosed as depression, Parkinson's disease, Alzheimer's disease, or other psychiatric conditions. This hinders the potential for implementing appropriate treatment for neurological conditions. Misdiagnosis often leads to delayed initiation of appropriate treatment for the underlying FTD. This can result in missed opportunities for interventions that could slow disease progression or manage symptoms effectively. Treating FTD patients based on misdiagnosed conditions can result in ineffective or even harmful treatments. Medications commonly used for depression or other psychiatric disorders may not address the specific cognitive, behavioral, and functional challenges of FTD. Without proper treatment, FTD symptoms can worsen over time, leading to greater impairment in daily functioning and quality of life. Misdiagnosis can lead to unnecessary medical expenses, as well as wasted time and resources on treatments that are unlikely to be effective. Accurate diagnosis is crucial for enrolling eligible patients in clinical trials for FTD-specific treatments. Misdiagnosis can exclude patients from potential participation and hinder the development of targeted therapies.

Key Market Trends

Higher Drug Approvals and Advanced Treatment

Several antidepressant drugs are utilized for the treatment of major depressive disorders and other conditions, such as dysthymia, obsessive-compulsive disorder (OCD), anxiety disorders, eating disorders, chronic pain, and neuropathic pain. For example, in October 2018, Lundbeck introduced Brintellix tablets for the treatment of Major Depressive Disorder in India. Similarly, in April 2019, Lupin launched antidepressant Fluoxetine tablets in the American market, specifically for the treatment of major depressive disorder and obsessive-compulsive disorder. These initiatives contribute significantly to the growth of the market.

Drug approvals provide patients with access to treatments that can potentially slow down disease progression, manage symptoms, and improve quality of life. This leads to higher demand for treatments among FTD patients and healthcare providers. Effective treatments often come with improved diagnostic methods, biomarkers, and screening tools. This facilitates early diagnosis and patient identification, leading to an increased pool of eligible patients seeking treatment. Approved treatments can contribute to better patient outcomes, including improved cognitive function, reduced behavioral symptoms, and enhanced daily functioning. Positive outcomes drive higher demand for these treatments. Drug approvals garner media attention and raise awareness among patients, caregivers, and the general public. This increased awareness leads to more individuals seeking diagnosis and treatment options for FTD. Successful drug approvals indicate a growing interest in FTD research and development. This encourages pharmaceutical companies, researchers, and investors to invest more resources into finding innovative treatments.

Key Market Players

• Transposon Therapeutics
• Alector Inc.
• Denali Therapeutics Inc.
• Pfizer Inc.
• Johnson & Johnson Services Inc.
• Prevail Therapeutics
• Wave Life Sciences
• AstraZeneca plc
• GlaxoSmithKline plc
• TauRx Pharmaceuticals Ltd.

Report Scope:

In this report, the Global Frontotemporal Dementia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Frontotemporal Dementia Market, By Drug Class:

• Cognitive Enhancers
• Antipsychotics
• Antidepressants
• CNS Stimulants
• Other Drug Classes

Frontotemporal Dementia Market, By Disease Indication:

• Frontotemporal Dementia
• Primary Progressive Aphasia
• Movement Disorders

Frontotemporal Dementia Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Frontotemporal Dementia Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Frontotemporal Dementia Market.

Available Customizations:

Global Frontotemporal Dementia market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

• 5.1. Ongoing Clinical Trials
• 5.2. Completed Clinical Trials
• 5.3. Terminated Clinical Trials
• 5.4. Breakdown of Pipeline, By Development Phase
• 5.5. Breakdown of Pipeline, By Status
• 5.6. Breakdown of Pipeline, By Study Application
• 5.7. Breakdown of Pipeline, By Region
• 5.8. Clinical Trials Heat Map

6. Global Frontotemporal Dementia Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class (Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants, and Other Drug Classes)
  • 6.2.2. By Disease Indication (Frontotemporal Dementia, Primary Progressive Aphasia, and Movement Disorders)
  • 6.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
  • 6.2.4. By Region
  • 6.2.5. By Company (2024)
• 6.3. Market Map

7. North America Frontotemporal Dementia Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Disease Indication
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Frontotemporal Dementia Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Disease Indication
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Canada Frontotemporal Dementia Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Disease Indication
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Mexico Frontotemporal Dementia Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Disease Indication
      • 7.3.3.2.3. By Distribution Channel

8. Europe Frontotemporal Dementia Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Disease Indication
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. Germany Frontotemporal Dementia Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Disease Indication
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. United Kingdom Frontotemporal Dementia Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Disease Indication
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Italy Frontotemporal Dementia Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecasty
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Disease Indication
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. France Frontotemporal Dementia Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Disease Indication
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Spain Frontotemporal Dementia Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Disease Indication
      • 8.3.5.2.3. By Distribution Channel

9. Asia-Pacific Frontotemporal Dementia Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Disease Indication
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Asia-Pacific: Country Analysis
  • 9.3.1. China Frontotemporal Dementia Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Disease Indication
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. India Frontotemporal Dementia Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Disease Indication
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Japan Frontotemporal Dementia Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Disease Indication
      • 9.3.3.2.3. By Distribution Channel
  • 9.3.4. South Korea Frontotemporal Dementia Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Drug Class
      • 9.3.4.2.2. By Disease Indication
      • 9.3.4.2.3. By Distribution Channel
  • 9.3.5. Australia Frontotemporal Dementia Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Drug Class
      • 9.3.5.2.2. By Disease Indication
      • 9.3.5.2.3. By Distribution Channel

10. South America Frontotemporal Dementia Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Disease Indication
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Frontotemporal Dementia Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Disease Indication
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Argentina Frontotemporal Dementia Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Disease Indication
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Colombia Frontotemporal Dementia Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Disease Indication
      • 10.3.3.2.3. By Distribution Channel

11. Middle East and Africa Frontotemporal Dementia Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Drug Class
  • 11.2.2. By Disease Indication
  • 11.2.3. By Distribution Channel
  • 11.2.4. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa Frontotemporal Dementia Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Drug Class
      • 11.3.1.2.2. By Disease Indication
      • 11.3.1.2.3. By Distribution Channel
  • 11.3.2. Saudi Arabia Frontotemporal Dementia Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Drug Class
      • 11.3.2.2.2. By Disease Indication
      • 11.3.2.2.3. By Distribution Channel
  • 11.3.3. UAE Frontotemporal Dementia Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Drug Class
      • 11.3.3.2.2. By Disease Indication
      • 11.3.3.2.3. By Distribution Channel

12. Market Dynamics

• 12.1. Drivers
• 12.2. Challenges

13. Market Trends & Developments

• 13.1. Recent Development
• 13.2. Mergers & Acquisitions
• 13.3. Product Launches

14. Global Frontotemporal Dementia Market: SWOT Analysis

15. Porter's Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Product

16. Competitive Landscape

• 16.1. Transposon Therapeutics
• 16.2. Alector Inc.
• 16.3. Denali Therapeutics Inc.
• 16.4. Pfizer Inc.
• 16.5. Johnson & Johnson Services Inc.
• 16.6. Prevail Therapeutics
• 16.7. Wave Life Sciences
• 16.8. AstraZeneca plc
• 16.9. GlaxoSmithKline plc
• 16.10. TauRx Pharmaceuticals Ltd.

17. Strategic Recommendations

18. About Us & Disclaimer